CA27.29

Gion, Massimo; Mione, R; Leon, Antonette E.; Lüftner, Diana; Molina, Rafael; Possinger, K.; Robertson, J.F.R.

doi:10.1016/s0959-8049(00)00396-8

Cited by 64 publications

(13 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They are carcinoembriogenic antigen (CEA), alpha-feto protein (FP), tissue polypeptide antigen (TPA) and some tumour associated carbohydrate antigens (TACA) like CA 15-3, CA 19-9, CA 50, CA 125 and CA 242. [27][28][29][30][31][32][33][34][35][36][37][38] Some recent studies have been focused on mucins as tumour markers. [25,[39][40][41][42][43][44][45][46][47][48] .…”

Section: Tumour Markers In Colorectal Carcinomamentioning

confidence: 99%

Mucin Macromolecules in Normal, Adenomatous, and Carcinomatous Colon: Evidence for the Neotransformation

Aksoy

Akinci

2004

Macromolecular Bioscience

View full text Add to dashboard Cite

Mucins are high molecular-weight glycoproteins having oligosaccharides attached to serine or threonine residues of the mucin core protein backbone by O-glycosidic linkages. They are major components of mucus, covering the luminal surfaces of epithelial respiratory, gastrointestinal and reproductive tracts, and responsible for its viscoelastic properties. The core proteins of mucins are encoded by different mucin genes. Aberrations in the cell surface carbohydrates including mucins have been regarded as a universal characteristic of the malignant transformation of cells. These alterations are considered to be relevant to the abnormal behaviour of cancer cells, such as altered cell adhesion or metastasis, and to the avoidance of immunological defence.

show abstract

Section: Tumour Markers In Colorectal Carcinomamentioning

confidence: 99%

Mucin Macromolecules in Normal, Adenomatous, and Carcinomatous Colon: Evidence for the Neotransformation

Aksoy

Akinci

2004

Macromolecular Bioscience

View full text Add to dashboard Cite

show abstract

“…ELISA binding studies were therefore also undertaken with the IgG of monoclonal antibody B27.29. B27.29 is the basis for a screening test administered to breast cancer patients to determine prognosis53 and is one of a very few anti‐MUC1 antibodies actually raised against the MUC1‐expressing tumor. B27.29 can therefore be considered to be a “mirror image” of the tumor and as such provides an excellent probe for testing the consequence of increasing the repeat number on MUC1 humoral immunogenicity.…”

Section: Resultsmentioning

confidence: 99%

Structural and dynamic consequences of increasing repeats in a MUC1 peptide tumor antigen

et al. 2005

View full text Add to dashboard Cite

MUC1 mucin is a large transmembrane glycoprotein whose extracelluler domain is composed of repeating units of a 20 amino acid sequence. In the cancer associated state, this protein expression becomes upregulated and underglycosylated. Previous studies, which show an enhanced binding of a 5-repeat over a 1-repeat MUC1 peptide to a panel of anti-MUC1 antibodies, have led us to investigate the structural and dynamic consequences of increasing repeat number. Two MUC1 peptides were studied: a 16mer corresponding to slightly less than one full repeat of the MUC1 tandem repeat sequence (GVTSAPDTRPAPGSTA) and a 40mer corresponding to two full repeats of the MUC1 sequence (VTSAPDTRPAPGSTAPPAHG)2. Isotopically labeled versions of these MUC1 peptides were cloned, expressed, purified, and evaluated structurally and dynamically using 15N- and 13C-edited NMR approaches. The data show that MUC1 structure, dynamics, and antibody binding affinity are invariant with increasing repeat number. In light of these results, we conclude that the enhanced antibody affinity of the 5-repeat over the 1-repeat MUC1 peptide is due to multivalency effects, and not due to the development of higher order structure in the longer length peptides. The implications of these results are discussed within the context of a multiple repeat MUC1 breast cancer vaccine design.

show abstract

“…A variety of biological tumor markers for breast cancer have been investigated, such as CEA [12]–[14], CA 153[15]–[16], CA27.29 [17], [18], CA549 [19], Her2 [20]–[24], Cytokeratin8/18 [25], [26], CYFRA21-1[27]–[29], TPS [30]–[32], TPA [33] and other markers. However, to our knowledge, only CEA and CA153 are utilized frequently in clinical practice for breast cancer.…”

Section: Discussionmentioning

confidence: 99%

Cytokeratin19-2g2, a Novel Fragment of Cytokeratin19 in Serum, Indicating a More Invasive Behavior and Worse Prognosis in Breast Cancer Patients

et al. 2013

View full text Add to dashboard Cite

BackgroundVarious studies have been searching for new tumor biomarkers for breast cancer for years. However, so far, few markers have been proved clinically useful except CA153. Based on knowledge that most adenocarcinomas including breast carcinoma expressed Cytokeratin19, the authors studied CK19-2G2,a novel fragment of cytokeratin19 shedding into serum in breast cancer patients.Patients and MethodsThe serum samples of four hundred and seventeen patients including three hundred and three (fifty-four DCIS and two hundred and forty-nine stage I-III) PBC patients and one hundred and fourteen MBC patients, eighty-one healthy controls and twenty-one breast benign disease patients were provided for measurement of CK19-2G2, CEA and CA153.The correlation between clinicopathological characters, prognosis and CK19-2G2 levels was further studied.ResultsThe serum CK19-2G2 levels in breast cancer patients were significantly higher than that in healthy and benign controls. For breast cancer patients, CK19-2G2 levels in MBC were significantly higher than that in PBC patients. The sensitivities of CK19-2G2 for breast carcinoma are as high as CEA and CA153, and up to 71% in MBC patients. Serum CK19-2G2 levels (≥2 mU/mL) were associated with pathological stages, tumor size (≥2 cm), lymph node involvement, and HER2 status. Multivariate analysis revealed that high serum CK19-2G2 level was an independent factor for relapse (P = 0.029) and death (P = 0.040) in breast cancer patients.ConclusionSerum CK19-2G2 may be an independent indicator for prognosis and a candidate marker for monitoring metastasis in breast cancer.

show abstract

CA27.29

Cited by 64 publications

References 28 publications

Mucin Macromolecules in Normal, Adenomatous, and Carcinomatous Colon: Evidence for the Neotransformation

Mucin Macromolecules in Normal, Adenomatous, and Carcinomatous Colon: Evidence for the Neotransformation

Structural and dynamic consequences of increasing repeats in a MUC1 peptide tumor antigen

Cytokeratin19-2g2, a Novel Fragment of Cytokeratin19 in Serum, Indicating a More Invasive Behavior and Worse Prognosis in Breast Cancer Patients

Contact Info

Product

Resources

About